<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616213</url>
  </required_header>
  <id_info>
    <org_study_id>PR104-1004</org_study_id>
    <secondary_id>PROACTA-PR-104-1004</secondary_id>
    <nct_id>NCT00616213</nct_id>
  </id_info>
  <brief_title>PR104 and G-CSF in Treating Patients With Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given With Prophylactic G-CSF in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proacta, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proacta, Incorporated</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in&#xD;
      bone marrow or peripheral blood and may help the immune system recover from the side effects&#xD;
      of chemotherapy. Giving PR-104 together with G-CSF may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given&#xD;
      together with G-CSF in treating patients with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of PR-104 in combination with filgrastim (G-CSF) in&#xD;
           patients with solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Characterize the safety of this regimen in these patients.&#xD;
&#xD;
        -  Evaluate the pharmacokinetics of PR-104 and its alcohol metabolite.&#xD;
&#xD;
        -  Evaluate the rate of hypoxia in various solid tumors using F-MISO PET&#xD;
           (18F-fluoromisonidazole positron emission tomography) imaging.&#xD;
&#xD;
        -  Assess for antitumor toxicity in these patients.&#xD;
&#xD;
        -  Collect plasma samples for the assessment of potential biomarkers of tumor hypoxia.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of PR-104.&#xD;
&#xD;
      Patients receive PR-104 IV over 1 hour on day 1 and filgrastim (G-CSF) on day 2. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      also undergo 18F-fluoromisonidazole PET scans at baseline and prior to course 3 to assess&#xD;
      tumor hypoxia.&#xD;
&#xD;
      Patients undergo blood sample collection periodically during course 1. Samples are analyzed&#xD;
      for the pharmacokinetics of PR-104 and for identification of biomarkers for tumor hypoxia.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of PR-104</measure>
    <time_frame>3 weeks (cycle 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile using CTCAE v3 criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicity of PR-104</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PR-104 and its alcohol metabolite in blood</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of tumor hypoxia</measure>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>filgrastim will be administered at a standard dose and schedule</description>
    <other_name>Neupogen</other_name>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR104</intervention_name>
    <description>PR104 is administered intravenously once every 21 days</description>
    <other_name>PR-104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>F-18-fluoromisonidazole</intervention_name>
    <description>F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan</description>
    <other_name>FMISO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL (no red blood cell transfusions allowed)&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PTT ≤ 1.5 times normal&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  ALT or AST ≤ 2 times ULN (≤ 5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  Able to read, understand, and provide written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Evidence of a significant medical disorder or laboratory finding that, in the opinion&#xD;
             of the investigator, compromises the patient's safety during study participation,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Uncontrolled infection or infection requiring a concomitant parenteral antibiotic&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Chronic renal disease&#xD;
&#xD;
               -  Coagulopathy (excluding prophylactic anticoagulation)&#xD;
&#xD;
          -  Known HIV positivity&#xD;
&#xD;
          -  Hepatitis B sAg-positive or known to be hepatitis C-positive with abnormal liver&#xD;
             function tests&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than 3 prior myelosuppressive chemotherapy regimens&#xD;
&#xD;
               -  Patients who have received more than 3 prior myelosuppressive regimens may be&#xD;
                  eligible, if considered to have adequate marrow, based on prior exposure to 1 of&#xD;
                  the following regimens:&#xD;
&#xD;
                    -  Minimally myelosuppressive regimens&#xD;
&#xD;
                    -  Limited courses of myelosuppressive regimens&#xD;
&#xD;
          -  More than 4 weeks since prior and no other concurrent licensed or investigational&#xD;
             anticancer treatment (6 weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  More than 24 hours since any prior radiotherapy and no likelihood of toxicity from&#xD;
             this therapy&#xD;
&#xD;
          -  More than 4 weeks since major surgery&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 20% of bone marrow&#xD;
&#xD;
          -  No prior high-dose chemotherapy (including either myeloablative or non-myeloablative&#xD;
             transplantations)&#xD;
&#xD;
          -  Prior and concurrent androgen deprivation therapy allowed&#xD;
&#xD;
          -  Concurrent systemic steroids allowed, provided the patient has been on a stable dose&#xD;
             for at least 2 weeks prior to first dose of PR-104&#xD;
&#xD;
          -  No concurrent irradiation therapy (palliative or therapeutic), unless given in the&#xD;
             absence of tumor progression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>2020</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>May 31, 2011</last_update_submitted>
  <last_update_submitted_qc>May 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Brenda Gibson, Assoc. Director</name_title>
    <organization>Proacta, Inc.</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

